Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 known ✓ | Q9UBN7 | 2/20 | 0.37 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.37 |
| ▸ | CACNA1G known ✓ | O43497 | 1/20 | 0.30 |
| ▸ | CACNA1B known ✓ | Q00975 | 1/20 | 0.30 |
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.30 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.30 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | CTSK | P43235 | 3/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | FPR3 | P25089 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL55404 | 0.98 | HDAC6 (0.38) | HDAC6HDAC1HDAC2CA14CTSK | |
| SCHEMBL1654128 | 0.93 | CA14 (0.40) | HDAC6HDAC1HDAC2CA14CTSK | |
| SCHEMBL23728825 | 0.91 | CHRM2 (0.39) | HDAC6HDAC1HDAC2CA14CTSK | |
| SCHEMBL22291496 | 0.91 | CHRM2 (0.42) | HDAC6HDAC1HDAC2CA14CTSK | |
| SCHEMBL18391125 | 0.91 | CHRM2 (0.42) | HDAC6HDAC1HDAC2CA14CTSK | |
| SCHEMBL2722798 | 0.91 | CHRM2 (0.42) | HDAC6HDAC1HDAC2CA14CTSK | |
| SCHEMBL28909787 | 0.91 | CHRM2 (0.42) | HDAC6HDAC1HDAC2CA14CTSK | |
| Hydrochloric Acid SCHEMBL1026855 | 0.89 | HDAC6 (0.35) | HDAC6HDAC1HDAC2CA14CTSK | |
| SCHEMBL7775532 | 0.88 | CHRM2 (0.39) | HDAC6HDAC1HDAC2CA14PDK2 | |
| SCHEMBL34414 | 0.86 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CA14CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250255973-A1 | HYDROGEL CROSS-LINKED HYALURONIC ACID PRODRUG COMPOSITIONS AND METHODS | ASCENDIS PHARMA GMBH (DE) | 2025-08-14 | — | — | US | disclosed |
| US-12246070-B2 | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods | ASCENDIS PHARMA A/S (DK) | 2025-03-11 | — | — | US | disclosed |
| CN-110891611-B | Hydrogel crosslinked hyaluronic acid prodrug compositions and methods | 阿森迪斯制药公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20230414770-A1 | HYDROGEL CROSS-LINKED HYALURONIC ACID PRODRUG COMPOSITIONS AND METHODS | ASCENDIS PHARMA A/S (DK) | 2023-12-28 | — | — | US | disclosed |
| US-11642415-B2 | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods | ASCENDIS PHARMA A/S (DK) | 2023-05-09 | — | — | US | disclosed |
| US-20220305136-A1 | ANTI-CTLA4 CONJUGATES | ASCENDIS PHARMA GMBH (DE) | 2022-09-29 | — | — | US | disclosed |
| CN-104892449-A | Preparation method and use of spermine analogs and medicinal salts thereof | WANG MEI | 2015-09-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230414770-A1 | HYDROGEL CROSS-LINKED HYALURONIC ACID PRODRUG COMPOSITIONS AND METHODS | CD44, HCAR3, HPSE | HDAC6 110/4885HDAC1 245/4885HDAC2 189/4885 |
| US-12246070-B2 | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods | CD44, HCAR3, HPSE | HDAC6 110/4885HDAC1 245/4885HDAC2 189/4885 |
| US-11642415-B2 | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods | CD44, HCAR3, HPSE | HDAC6 110/4885HDAC1 245/4885HDAC2 189/4885 |
| US-20250255973-A1 | HYDROGEL CROSS-LINKED HYALURONIC ACID PRODRUG COMPOSITIONS AND METHODS | CD44, HCAR3, HPSE | HDAC6 110/4885HDAC1 245/4885HDAC2 189/4885 |
| US-20220305136-A1 | ANTI-CTLA4 CONJUGATES | CD274, PDCD1LG2, PDCD1 | HDAC6 84/4885HDAC1 190/4885HDAC2 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.